Prognostic biomarkers in cardiovascular diseases

Kanakeswary Karisnan; Mohammad Nazmul Hasan Maziz; Teguh Haryo Sasongko; Barani Karikalan; Ruziah Ibrahim; Isriyanti Mohd Rafae; Amuthaganesh Mathialagan

doi:10.53730/ijhs.v6nS2.5672

Authors

Kanakeswary Karisnan
kana.karisnan@qiu.edu.my
QUEST International University, Faculty of Medicine, Ipoh, Perak
Mohammad Nazmul Hasan Maziz Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, Malaysia
Teguh Haryo Sasongko Perdana University-Graduate School of Medicine, Perdana University, Kuala Lumpur, Malaysia
Barani Karikalan Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, Malaysia
Ruziah Ibrahim Perdana University-Royal College of Surgeons Ireland, Perdana University, Kuala Lumpur, Malaysia
Isriyanti Mohd Rafae Perdana University-Royal College of Surgeons Ireland, Perdana University, Kuala Lumpur, Malaysia
Amuthaganesh Mathialagan Perdana University-Royal College of Surgeons Ireland, Perdana University, Kuala Lumpur, Malaysia

Keywords:

prognostic biomarkers, cardiovascular diseases, primary healthcare, cTnT, BNP

Abstract

The use of biomarkers as a reliable and reproducible indicative of the risk, severity, and progression of cardiovascular diseases (CVDs) may greatly enhance the prognostic capability of primary healthcare clinicians. In primary healthcare, the realistic and wise use of reliable biomarkers could minimize the time and costs for effective diagnosis and suitable personalized therapy for CVD patients. Therefore, the aim of the present scoping review is to evaluate the prognostic significance of biomarkers in the progression and monitoring of CVDs. The review was conducted according to the PRISMA-ScR guidelines. Eight databases were searched for articles published as of June 2021 using search terms: cardiovascular diseases AND biomarkers AND prognosis. A total of 21 studies were included in this scoping review. This review identified biomarkers BNP, cTnT yielded better accuracy of disease progression prediction in ACS and HF respectively. The availability of CVDs prognostic biomarkers in primary healthcare clinics could promote improved clinical outcomes of patients.

Downloads

Download data is not yet available.

References

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR et al. . M doi: 10. 1161/CIR. 0000000000000659. E in: C 2020 J 14;141(2):e33. P 30700139. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528.

Deaton C, Froelicher ES, Wu LH, Ho C, Shishani K JT. . The global burden of cardiovascular disease. Eur J Cardiovasc Nurs. 2011;10(2):00111–3.

Yusuf S, Reddy S, Ôunpuu S AS. . . Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–53.

CDC. https://www.cdc.gov/globalhealth/healthprotection/ncd/cardiovascular-diseases. https://www.cdc.gov/globalhealth/healthprotection/ncd/cardiovascular-diseases.

Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics–2012 update: A report from the American Heart Association. Circulation. 2012;125:e2–e220.

Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, Mente A YS. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res. 2017;121():.(6):677-694. doi:10.1161/CIRCRESAHA.117.308903.

Vasan RS. Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations. Circulation. 2006;113:2335–2362.

Dhingra R VR. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med. 2017;27(2):123-133. doi:doi:10.1016/j.tcm.2016.07.005

Sunil K Nadar and Muhammed Mujtaba Shaikh. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50–56.

McLean, A. S., Huang, S. J., & Salter M. Bench-to-bedside review: the value of cardiac biomarkers in the intensive care patient. Crit care. 2008;12(3):215. doi:10.1186/cc6880

Hemingway H, Henriksson M, Chen R, Damant J, Fitzpatrick NK, Abrams K et al. The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision-model. Heal Technol Assess. 2010;14.

Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Hear J. 2006;27:1341-1381.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M et al. . Markers of inflammation and cardiovascular disease: application to clinical and public health practice—a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL BDB 2D SG. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med. 2015;373(7):610-620.

Bruno G, Landi A, Barutta F et al. N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care. 2013;36(9):2677-2682.

Gerstein HC, Paré G, McQueen MJ et al; . Outcome Reduction With Initial Glargine Intervention Trial Investigators. Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation. 2015;132(24):2297-2304.

Arksey, H., & O’Malley L. Scoping Studies: Towards a Methodological Framework. Vol 8.; 2005.

Levac, D., Colquhoun, H., & O’Brien KK(). Scoping studies: Advancing the methodology. Implement Sci. 2010;5:1–9. doi:10.1186/1748‐5908‐5‐69

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473.

Mingels AM, Joosen IA, Versteylen MO, Laufer EM, Winkens MH, Wildberger JE, Van Dieijen-Visser MP HL. High-sensitivity cardiac troponin T: risk stratification tool in patients with symptoms of chest discomfort. PLoS One. 2012;7(4):e35059. doi:10.1371/journal.pone.0035059

Mirabet S, García-Osuna A, Garcia de Frutos P, Ferrero-Gregori A, Brossa V, Lopez L, Leta R, Garcia-Picart J, Padro JM, Sánchez-Quesada JL, Cinca J, Ordonez-Llanos J RE. High-Sensitivity Troponin T and Soluble Form of AXL as Long-Term Prognostic Biomarkers after Heart Transplantation. Dis Markers. Published online 2018:6243529. doi:10.1155/2018/6243529

James SK, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L LB. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol. 2006;48(6):1146-1154.

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E et al. CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial. Scand J Clin Lab Invest. 2011;71(1):52-62. doi:10.3109/00365513.2010.538081.

Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM BE. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005;294(22):2866-2871.

Tang WH, Iqbal N, Wu Y HS. Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status. Am J Cardiol. 2013;111(4):465-470. doi:10.1016/j.amjcard.2012.10.027

Schindler EI, Szymanski JJ, Hock KG, Geltman EM SM. Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults. Clin Chem. 2016;62(2):360-366. doi:10.1373/clinchem.2015.246553.

Gurel OM, Yilmaz H, Celik TH, Cakmak M, Namuslu M, Bilgiç AM, Bavbek N, Akcay A EB. Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. Herz. 2015;40(5):788-794. doi:0.1007/s00059-015-4303-6

Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H WKO 5;. doi: E 2010 S 20. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387-1395. doi:10.1161/CIRCULATIONAHA.109.928846.

Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A WL. STABILITY Investigators. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017;63(1):325-333. doi:10.1373/clinchem.2016.260570

Rehman SU JJ. Natriuretic Peptide testing in primary care. Curr Cardiol Rev. 2008;4(4):300-308. doi:doi:10.2174/157340308786349499

Gerber, Y., Jaffe, A. S., Weston, S. A., Jiang, R., & Roger VL. Prognostic value of cardiac troponin T after myocardial infarction: a contemporary community experience. Mayo Clin Proc. 2012;87(3):247–254. doi:https://doi.org/10.1016/j.mayocp.2011.11.013

Chow, S. L., Maisel, A. S., Anand, I., Bozkurt, B., de Boer, R. A., Felker, G. M., Fonarow, G. C., Greenberg, B., Januzzi, J. L., Jr, Kiernan, M. S., Liu, P. P., Wang, T. J., Yancy, C. W., Zile, M. R., & American Heart Association Clinical Pharmacology Co P and RC on E and PC on FG and TB and C on Q of C and OR. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135(2):e1054–e1091. doi:https://doi.org/10.1161/CIR.0000000000000490

Horwich TB, Patel J, MacLellan WR FG. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108(7):833-838. doi:10.1161/01.CIR.0000084543.79097.34

Janata KM, Leitner JM, Holzer-Richling N, Janata A, Laggner AN JB. Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism. Eur Respir J. 2009;34(6):1357-1363. doi:10.1183/09031936.00033109

Rottbauer W, Greten T, Müller-Bardorff M et al. ;. doi:10. 1093/eurheartj/17. suppl_f. . Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage. Eur Hear J. 1996;17(Suppl F):3-8.

Aydin S, Ugur K, Aydin S, Sahin İ YM. Biomarkers in acute myocardial infarction: current perspectives. Vasc Heal Risk Manag. 2019;15:1-10. doi:10.2147/VHRM.S166157

Twerenbold R, Boeddinghaus J, Nestelberger T et al. Clinical Use of High-Sensitivity Cardiac Troponin in Patients With Suspected Myocardial Infarction. Am Coll Cardiol J. 2017;70(8):996-1012. doi:10.1016/j.jacc.2017.07.718

J M. High-sensitivity cardiac troponins in everyday clinical practice. World J Cardiol. 2014;6(4):175–182. doi:https://doi.org/10.4330/wjc.v6.i4.175

Cook, C., Cole, G., Asaria, P., Jabbour, R., & Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368–376. doi:https://doi.org/10.1016/j.ijcard.2013.12.028

de Lemos JA L-JD. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008;358(20):2172-2174. doi:doi:10.1056/NEJMe0801721

Ruwanpathirana T, Owen A RC. Review on cardiovascular risk prediction. Cardiovasc Ther. 2015;33(2):62-70. doi:10.1111/1755-5922.1211

Chapman AR, Leslie SJ, Walker SW, Bickler C DM. Potential costs of B-type natriuretic peptide for the identification of people with heart failure in primary care in Scotland - a pilot study. J R Coll Physicians Edinb. 2015;45(1):27-32. doi:doi:10.4997/JRCPE.2015.107

Tarride JE, Lim M, DesMeules M et al. A review of the cost of cardiovascular disease. Can J Cardiol. 2009;25(6):e195-e202. doi:doi:10.1016/s0828-282x(09)70098-4

Schade DS, Obenshain SS, Ramo B ER. A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United States. Am J Med. 2019;132(12):1365-1367. doi:10.1016/j.amjmed.2019.03.043

R S. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7(1):33–47. doi:https://doi.org/10.2217/pme.09.49

Amu S, LaVange L, ZinehI B-GS and W. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. Clin Pharmacol Ther J. 2015;98:1.

Batlle M, Campos B, Farrero M, Cardona M, González B, Castel MA, Ortiz J, Roig E, Pulgarín MJ, Ramírez J et al. Use of serum levels of high sensitivity troponin T, galectin-3 and C-terminal propeptide of type I procollagen at long term follow-up in heart failure patients with reduced ejection fraction: Comparison with soluble AXL and BNP. Int J Cardiol. 2016;225:113-119. doi:10.1016/j.ijcard.2016.09.079

Sato Y, Yamamoto E, Sawa T, Toda K, Hara T, Iwasaki T, Fujiwara H TY. High-sensitivity cardiac troponin T in essential hypertension. J Cardiol. 2011;58(3):226-231. doi:10.1016/j.jjcc.2011.07.009.

Mjelva ØR, Pönitz V, Brügger-Andersen T, Grundt H, Staines H ND. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome. Eur J Prev Cardiol. 2016;23():(11):1130-1140. doi:10.1177/2047487315619733

Desmoulin F, Galinier M, Trouillet C, Berry M, Delmas C, Turkieh A, Massabuau P, Taegtmeyer H, Smih F RP. Metabonomics analysis of plasma reveals the lactate to cholesterol ratio as an independent prognostic factor of short-term mortality in acute heart failure. PLoS One. 2013;8(4):e60737. doi:10.1371/journal.pone.0060737

Lee CW, Ahn JM, Park DW, Kim YH, Hong MK, Song JK, Kim JJ, Park SW, Chi HS PS. Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty. Atherosclerosis. 2008;196(1):327-332.

De Rosa R, De Rosa S, Leistner D, Boeckel JN, Keller T, Fichtlscherer S, Dimmeler S ZA. Transcoronary Concentration Gradient of microRNA-133a and Outcome in Patients With Coronary Artery Disease. Am J Cardiol. 2017;120(1):15-24. doi:10.1016/j.amjcard.2017.03.264

Zhang X, Nie X, Yuan S, Li H, Fan J, Li C, Sun Y, Zhao Y, Hou H, Wang DW CC. Circulating Long Non-coding RNA ENST00000507296 Is a Prognostic Indicator in Patients with Dilated Cardiomyopathy. Mol Ther Nucleic Acids. 2019;7(16):82-90. doi:10.1016/j.omtn.2019.02.004

El Amrousy D, Hodeib H, Suliman G, Hablas N, Salama ER EA. Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure. Pediatr Cardiol. 2017;38(2):418-424. doi:10.1007/s00246-016-1532-2

Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H KH. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Hear Inst J. 2012;39(1):30-35.

Kontny F, Andersen T, Ueland T, Åkerblom A, Lakic TG, Michelsen AE, Aukrust P, Bertilsson M, Becker RC, Himmelmann A, James SK, Siegbahn A,, Storey RF WL. PLATO Investigators. Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. Eur Hear J Acute Cardiovasc Care. Published online 2019:2048872619846334. doi:10.1177/2048872619846334

Dieplinger B, Egger M, Haltmayer M, Kleber ME, Scharnagl H, Silbernagel G, de Boer RA, Maerz W MT. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2014;60(3):530-540. doi:10.1373/clinchem.2013.209858

Wallace, T. W., Abdullah, S. M., Drazner, M. H., Das, S. R., Khera, A., McGuire, D. K., Wians, F., Sabatine, M. S., Morrow, D. A., & de Lemos JA. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113(16):1958–1965. doi:https://doi.org/10.1161/CIRCULATIONAHA.105.609974

Lopez-Calle, E., Espindola, P., Spinke, J., Lutz, S., Nichtl, A., Tgetgel, A., Herbert, N., Marcinowski, M., Klepp, J., Fischer, T., Brueckner, T., Boehm, C., & Keller T. A new immunochemistry platform for a guideline-compliant cardiac troponin T assay at the point of care: proof of principle. Clin Chem Lab Med. 2017;55(11):1798–1804. doi:https://doi.org/10.1515/cclm-2016-1078